<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aldeyra The — News on 6ix</title>
<link>https://6ix.com/company/aldeyra-the</link>
<description>Latest news and press releases for Aldeyra The on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Feb 2026 12:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aldeyra-the" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835451a78dffbe2df0e26a6.webp</url>
<title>Aldeyra The</title>
<link>https://6ix.com/company/aldeyra-the</link>
</image>
<item>
<title>Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-oppenheimer-36th-120100116</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-oppenheimer-36th-120100116</guid>
<pubDate>Wed, 18 Feb 2026 12:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., February 18, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate virtually in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.</description>
</item>
<item>
<title>Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-pdufa-extension-003000086</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-pdufa-extension-003000086</guid>
<pubDate>Tue, 16 Dec 2025 00:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., December 16, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026.</description>
</item>
<item>
<title>Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-expansion-rasp-120000154</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-expansion-rasp-120000154</guid>
<pubDate>Thu, 13 Nov 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 13, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided updated manufacturing information on reproxalap.</description>
</item>
<item>
<title>Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-jefferies-global-120100976</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-jefferies-global-120100976</guid>
<pubDate>Tue, 11 Nov 2025 12:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 11, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London, England.</description>
</item>
<item>
<title>Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-host-research-development-120000750</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-host-research-development-120000750</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 06, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the company will host a Research & Development Update webcast on Thursday, November 13, 2025 at 8:00 a.m. ET.</description>
</item>
<item>
<title>Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-positive-results-110100927</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-positive-results-110100927</guid>
<pubDate>Tue, 28 Oct 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., October 28, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of statistically significant improvement in liver function in patients treated with ADX-629, an investigational new drug candidate, and focused the RASP modulator product candidate pipeline on next-generation molecules ADX-248 and ADX-246.</description>
</item>
<item>
<title>Alkermes Appoints Joshua Reed as Chief Financial Officer</title>
<link>https://6ix.com/company/aldeyra-the/news/alkermes-appoints-joshua-reed-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/alkermes-appoints-joshua-reed-as-chief-financial-officer</guid>
<pubDate>Fri, 12 Sep 2025 13:00:00 GMT</pubDate>
<description>Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee.</description>
</item>
<item>
<title>Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-h-c-110100776</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-h-c-110100776</guid>
<pubDate>Wed, 03 Sep 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., September 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.</description>
</item>
<item>
<title>Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-orphan-designation-110100779</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-orphan-designation-110100779</guid>
<pubDate>Thu, 28 Aug 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., August 28, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects appro</description>
</item>
<item>
<title>Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-fast-track-110100589</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-fast-track-110100589</guid>
<pubDate>Tue, 19 Aug 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., August 19, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigment</description>
</item>
<item>
<title>Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-h-c-110100628</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-h-c-110100628</guid>
<pubDate>Wed, 06 Aug 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., August 06, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025.</description>
</item>
<item>
<title>Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-orphan-designation-110000718</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-orphan-designation-110000718</guid>
<pubDate>Thu, 24 Jul 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., July 24, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized</description>
</item>
<item>
<title>Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-fda-acceptance-110000754</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-announces-fda-acceptance-110000754</guid>
<pubDate>Thu, 17 Jul 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., July 17, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025.</description>
</item>
<item>
<title>Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-special-protocol-110000758</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-special-protocol-110000758</guid>
<pubDate>Thu, 26 Jun 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., June 26, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently lacking FDA-approved therapy.</description>
</item>
<item>
<title>Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-resubmits-reproxalap-drug-110000797</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-resubmits-reproxalap-drug-110000797</guid>
<pubDate>Tue, 17 Jun 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., June 17, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Per FDA agreement, the only new</description>
</item>
<item>
<title>Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-2025-jefferies-110100803</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-participate-2025-jefferies-110100803</guid>
<pubDate>Thu, 29 May 2025 11:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., May 29, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York.</description>
</item>
<item>
<title>Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-achieves-primary-endpoint-223400713</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-achieves-primary-endpoint-223400713</guid>
<pubDate>Mon, 05 May 2025 22:34:00 GMT</pubDate>
<description>LEXINGTON, Mass., May 05, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. For the prespecifie</description>
</item>
<item>
<title>Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-schedules-conference-call-200000907</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-schedules-conference-call-200000907</guid>
<pubDate>Mon, 05 May 2025 20:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., May 05, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media</description>
</item>
<item>
<title>Aldeyra Therapeutics Appoints Chip Clark to Board of Directors</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-appoints-chip-clark-110000817</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-appoints-chip-clark-110000817</guid>
<pubDate>Thu, 17 Apr 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., April 17, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company’s board of directors.</description>
</item>
<item>
<title>Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease</title>
<link>https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-complete-response-120000358</link>
<guid isPermaLink="true">https://6ix.com/company/aldeyra-the/news/aldeyra-therapeutics-receives-complete-response-120000358</guid>
<pubDate>Thu, 03 Apr 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., April 03, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing</description>
</item>
</channel>
</rss>